0001354488-14-005050.txt : 20141015 0001354488-14-005050.hdr.sgml : 20141009 20141009161134 ACCESSION NUMBER: 0001354488-14-005050 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20141009 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20141009 DATE AS OF CHANGE: 20141009 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharma-Bio Serv, Inc. CENTRAL INDEX KEY: 0001304161 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] IRS NUMBER: 200653570 FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50956 FILM NUMBER: 141150275 BUSINESS ADDRESS: STREET 1: INDUSTRIAL ZONE STREET 1 STREET 2: LOT 14 CITY: DORADO STATE: PR ZIP: 00646 BUSINESS PHONE: 787-278-2709 MAIL ADDRESS: STREET 1: INDUSTRIAL ZONE STREET 1 STREET 2: LOT 14 CITY: DORADO STATE: PR ZIP: 00646 FORMER COMPANY: FORMER CONFORMED NAME: LAWRENCE CONSULTING GROUP INC DATE OF NAME CHANGE: 20040923 8-K 1 pbsv_8k.htm CURRENT REPORT pbsv_8k.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): October 9, 2014
 
Pharma-Bio Serv, Inc.
(Exact Name of Registrant as Specified in Its Charter)
 
Delaware
(State or Other Jurisdiction of Incorporation)
 
0-50956
20-0653570
(Commission File Number)
(I.R.S. Employer Identification No.)

6 Road 696, Dorado, Puerto Rico
00646
(Address of Principal Executive Offices)
(Zip Code)

(787) 278-2709
(Registrant’s Telephone Number, Including Area Code)

 
 
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
 
Item 8.01.  Other Events.
 
On October 9, 2014, Pharma-Bio Serv, Inc. issued a press release announcing its Collaboration Agreement with Quality Technical Iberica, S.L.  A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

Item 9.01.  Financial Statements and Exhibits.

(d) Exhibits.
 
Exhibit No.   Exhibit Description
     
99.1   Press Release
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Date: October 9, 2014 PHARMA-BIO SERV, INC.  
       
 
By:
/s/ Pedro J. Lasanta  
    Pedro J. Lasanta  
    Chief Financial Officer and Vice President Finance and Administration  
       
 
 
 
 
 
 

EXHIBIT INDEX
 
Exhibit No.   Exhibit Description
     
99.1   Press Release
EX-99.1 2 pbsv_ex991.htm PRESS RELEASE pbsv_ex991.htm
EXHIBIT 99.1
 
Pharma-Bio Serv Signs Strategic Collaboration Agreement with Quality Technical Iberica, S.L.

DORADO, PUERTO RICO, October 9, 2014 – Pharma-Bio Serv. (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, announced today that it has signed a three-year strategic collaboration agreement with Quality Technical Iberica, S.L (“QTI”), a Spain-based company specializing in Calibrations, Validation, HVAC and Clean Room Qualification services.

Under the agreement, QTI will provide technical advisory consulting assistance for establishing a new Pharma-Bio Serv, Puerto Rican-based Calibrations Services Division that will develop and operate a central metrology/calibration laboratory and provide lab and field calibration, verification and qualification of equipment and installations, readiness audits, HVAC and clean room qualification and related services.  Pharma-Bio Serv will market these services through the new division.

“Our alliance with QTI is a significant milestone which allows us to serve our clients’ needs by expanding our portfolio of services”, said Ms. Elizabeth Plaza, Principal Executive Officer of Pharma-Bio Serv. “We look forward to a fruitful and highly productive relationship with QTI and a bright future together,” Ms. Plaza added.

“We are especially pleased to support Pharma-Bio Serv goals for their new Calibration Services Division,” said Valentin Martinez, President of QTI. “Our work together will yield exceptional client service offerings from Pharma-Bio Serv,” he added.

About Quality Technical Iberica, S.L.

Quality Technical Iberica, S.L., is a Spain-based company with 15 years of experience and a market share of approximately 70% within the Spanish market for Calibrations, Validation, HVAC and Clean Room Qualification services.
 
About Pharma-Bio Serv Inc.

Pharma-Bio Serv is a compliance, project management and technology transfer support consulting firm, headquartered in Puerto Rico, with operations in the U.S., Ireland and Spain. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance related services with integrated portfolio services including microbiological and chemical testing services for clients in the Pharmaceutical, Biotechnology, Chemical, Medical Device, Cosmetic, Food and Allied Products industries, at its laboratory testing facility in Puerto Rico. Services also include "Integratek," an information technology consulting practice, and "Pharma Serv Academy" a division that provides technical and regulatory standards seminars/training conducted by industry experts. The Company's global team includes more than 300 leading engineering and life science professionals, quality assurance managers and directors.

Forward Looking Statements

This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this news release. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this news release, forward-looking statements are inherently subject to significant business risks, economic and competitive uncertainties, or other contingencies, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2013 and in its other filings with the Securities and Exchange Commission, which filings are available on www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

Investor Relations Contact:
Scott Gordon
President
CorProminence LLC
scottg@corprominence.com
631 703 4900